

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/269,711	04/05/1999	TAKESHI SAKAI	1/F3511PTUS	1469
513 7	7590 06/21/2002			
WENDEROTH, LIND & PONACK, L.L.P.			EXAMINER	
2033 K STREI SUITE 800			WANG, SHENGJUN	
WASHINGTON, DC 20006-1021			ART UNIT	PAPER NUMBER
			1617	
			DATE MAILED: 06/21/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

v	Applicati n No.	Applicant(s)				
Advisory Action	09/269,711	SAKAI ET AL.				
Advicery Action	Examiner	Art Unit				
1	Shengjun Wang	1617				
The MAILING DATE of this communication appears n the cover sheet with the c rrespondence address						
THE REPLY FILED 31 May 2002 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.						
PERIOD FOR REPLY [check either a) or b)]						
a) The period for reply expires 3 months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.						
2. The proposed amendment(s) will not be entered because:						
(a) 🔯 they raise new issues that would require further consideration and/or search (see NOTE below);						
(b) they raise the issue of new matter (see Note below);						
(c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
(d) they present additional claims without cancell	ng a corresponding number of fi	nally rejected claims.				
NOTE: See Continuation Sheet.						
3. Applicant's reply has overcome the following rejection(s):						
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).						
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.						
5. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.						
7. For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.						
The status of the claim(s) is (or will be) as follows:		·				
Claim(s) allowed: <i>None</i> .						
Claim(s) objected to: None.						
Claim(s) rejected: 40-47.						
Claim(s) withdrawn from consideration: None.						
8. The proposed drawing correction filed on is a) approved or b) disapproved by the Examiner.						
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)						
10. Other:		SELL TRAVERS MARY EXAMINER GROUP 1200				

U.S. Patent and Trademark Office TO-303 (Rev. 04-01) Continuati n Sheet (PTO-303)

Applicati n N . 009/269,711

Continuation of 2. NOTE: The proposed aniendments would substantially change the scope or claimed invention and would require further search and consideration..

Continuation of 5. does NOT place the application in condition for allowance because: of the reasons set forth in the prior office action. Particularly, since the proposed amendments would not be entered, argumenst that the cited references do not teach expressly the employment of glycerolipid are moot. It is noted that the claimed invention is very broad, it does not have any limitation with respect to the subject being treated, and the amount of the active ingredient administered. Any one who administer glycerolipid and/or glyceroglycolipid would effectively practice the claimed invention.